Join this session to discuss the challenges of and strategies for coordinating care for patients receiving therapies such as bispecific antibodies or chimeric antigen receptor (CAR) T-cell therapy in academic and community settings.
Identify challenges associated with transitioning care from inpatient to outpatient in the setting of immunotherapy agents with risk of cytokine release syndrome (CRS) or immune effector cell associated neurotoxicity (ICANS)
Discuss inpatient and outpatient CRS management of bispecific antibody therapies and indications for readmission
Demonstrate confidence in the management of bispecific antibody therapies in the community setting
Manager of Advanced Practice Services,
University of Chicago Medical Center
UT MD Anderson Cancer Center